Neuronetics Completes $18 Million Public Offering of Common Stock
Neuronetics, Inc. (NASDAQ: STIM) has successfully priced its underwritten public offering, raising approximately $18 million through the sale of 8,000,000 shares of common stock at a price of $2.25 per share. This strategic financial move aims to bolster the company's initiatives in mental health treatment and expand its offerings.
Overview of the Offering
The company has also provided the underwriter with a 30-day option to acquire an additional 1,200,000 shares at the public offering price, which will further augment the funds available for operational expenditures. All shares sold in this offering are being issued by Neuronetics, showcasing a robust commitment to enhancing its capital structure.
Intended Use of Proceeds
Neuronetics plans to allocate the net proceeds from this offering towards various general corporate purposes. These include advancing sales and marketing strategies, investing in research and development, financing potential acquisitions, enhancing healthcare practices, and managing working capital. This diversified approach signals the company's commitment to sustaining growth and innovation within the mental health sector.
Execution by Canaccord Genuity LLC
Canaccord Genuity LLC serves as the sole bookrunner for this offering. The collaboration between Neuronetics and Canaccord Genuity reflects a shared vision of growth and the capacity to effectively navigate the public markets.
About Neuronetics and NeuroStar Therapy
Neuronetics, based in Malvern, Pennsylvania, stands as a pioneer in the neuroscience domain, focusing on mental health solutions. The company's flagship treatment, NeuroStar Advanced Therapy, offers a non-invasive alternative for those grappling with neurohealth issues, particularly when conventional pharmaceuticals have failed to yield favorable outcomes.
Treatment Efficacy of NeuroStar
NeuroStar Therapy has revolutionized treatment options for depression and anxiety, providing significant relief for patients diagnosed with major depressive disorder (MDD) and experiencing comorbid anxiety symptoms. Specifically, it targets adults who have encountered limited success with prior antidepressant medication. The U.S. Food and Drug Administration has recognized NeuroStar Therapy not only as an effective treatment for depression but also for obsessive-compulsive disorder, enhancing its versatility in therapeutic applications.
Investing in the Future
The insightful use of funds from the recent offering will allow Neuronetics to continue transforming the landscape of mental health treatment. By fostering innovation and improving access to advanced therapies, the company remains dedicated to enhancing patients' quality of life. The ongoing commitment to research by Neuronetics helps pave the way for future advancements in mental health solutions.
Commitment to Patients and Physicians
Neuronetics is unwavering in its commitment to providing transformative treatment options that produce remarkable results. Through its network of Greenbrook TMS treatment centers, the company effectively delivers its therapies to individuals looking for alternatives that prioritize their mental wellness.
Frequently Asked Questions
What is the purpose of the $18 million offering by Neuronetics?
The proceeds from the offering are intended to support general corporate purposes, including marketing, R&D, acquisitions, and working capital.
How many shares were sold in this public offering?
Neuronetics sold 8,000,000 shares of common stock at a public offering price of $2.25 per share.
Who is handling the offering process for Neuronetics?
Canaccord Genuity LLC is serving as the sole bookrunner for this public offering.
What therapy is Neuronetics known for?
Neuronetics is known for its NeuroStar Advanced Therapy, a non-invasive treatment for various neurohealth conditions, including depression and anxiety.
Where can investors find more information about the offering?
Investors can access additional information on the offering through the filings made with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC's website.
